Eylea ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
90	網膜色素変性症	2
166	弾性線維性仮性黄色腫	2

90. 網膜色素変性症

---

臨床試験数 : 130 /  薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02661711 (ClinicalTrials.gov)	March 2016	13/1/2016	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study	Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)	Macular Oedema;Retinitis Pigmentosa	Drug: Aflibercept	Moorfields Eye Hospital NHS Foundation Trust	Bayer	Active, not recruiting	16 Years	N/A	Both	30	Phase 2	United Kingdom
2	EUCTR2015-003723-65-GB (EUCTR)	12/01/2016	06/01/2016	Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eye	Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR	Retinitis Pigmentosa associated Cystoid Macular Oedema MedDRA version: 18.1;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Eylea Product Name: Eylea Product Code: n/a INN or Proposed INN: Aflibercept	Moorfields Eye Hospital	NULL	Not Recruiting			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

166. 弾性線維性仮性黄色腫

---

臨床試験数 : 15 /  薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02537054 (ClinicalTrials.gov)	September 2015	21/8/2015	Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Aflibercept	University Hospital, Bonn	NULL	Completed	18 Years	65 Years	All	15	Phase 2	Germany
2	EUCTR2014-005263-33-DE (EUCTR)	29/04/2015	26/02/2015	Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum	Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP	Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Eylea	Medizinische Fakultät der Universität Bonn	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 2	Germany